ALLR

0.78509.25%
JL

Jose L. Iglesias

Consultant Chief Medical Officer

Dr. Jose L. Iglesias, M.D. is Clinical Advisor of HiberCell, Inc. is Scientific Advisor (Clinical) of Engine Biosciences Pte. Ltd. He was Chief Medical Affairs Officer of Agenus Inc. from November 10, 2025 to March 2026. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France’s Autorisation d’Accès Compassionnel (AAC) program. Dr. Iglesias has global oncology and immuno-oncology drug development experience. He was Chief Medical Officer of HiberCell, Inc. Dr. Iglesias is Member of Clinical Advisory Board of Amplia Therapeutics Limited. He serves as Consultant Chief Medical Officer of Allarity Therapeutics, Inc. since October 2024. Previously, at Abraxis BioScience and Celgene, he led late-stage development and life-cycle management of Abraxane in pancreatic, lung and metastatic breast cancers, supporting its integration into routine practice across these tumor types. Most recently, Dr. Iglesias served in senior medical leadership roles at Bionomics, Biothera and Apobiologix, where he directed global oncology programs across biologics, small molecules and immunotherapies. In his new role, Dr. Iglesias will oversee global medical affairs strategy for BOT/BAL, including medical evidence generation, communications and scientific exchange with clinicians, investigators and health authorities. He will also guide appropriate use of BOT/BAL within regulatory and early-access frameworks worldwide, including France’s AAC program, with a focus on robust data collection and real-world evidence. He is Chief Medical Officer of Racura Oncology Ltd (formerly known as Race Oncology Limited) from May 5, 2025. He serves as Director of Apex Oncology Consulting Inc. He served as Chief Medical Advisor at Senti Biosciences, Inc. since January 2020 until July 2022. He served as Chief Medical Officer at Senti Biosciences, Inc. since March 2020. Dr. Iglesias leads the clinical development of Senti’s next-generation cell and gene therapy product candidates focused on the treatment of solid and liquid tumors. He serves as Member of Scientific & Clinical Advisory Committee at IMV Inc. He serves as the Consulting Chief Medical Officer at PharmaCyte Biotech, Inc. since August 2020. Dr. Iglesias has been Medical Director of Oncology at Cycle Solutions, Inc. (also known as ResearchPoint Global) since May 2018. Dr. Iglesias was Chairperson of the Medical Oncology Advisory Board and Consultant Chief Medical Officer at Bioasis Technologies Inc. since December 2019 until March 4, 2020. Dr. Iglesias had been Scientific Advisor at Bionomics Ltd., since February 25, 2016 until 2019. Dr. Iglesias serves as Chief Medical Officer (CMO) at Biothera, US. Dr. Iglesias served as a Senior Medical Advisor of Biothera, Inc. since November 25, 2016 until January 6, 2017. He served as the Oncology Medical Advisor of Bionomics Ltd. from October 22, 2015 to February 25, 2016 and served as its Chief Medical Officer from November 1, 2012 to October 15, 2015. He served as Chief Medical Officer of Abraxis BioScience, Inc. since May 2008 and served as its Vice President of BostonGlobal Clinical Development since November 2007. He served as Vice President of Global Clinical Development & Medical Affairs for Abraxis Oncology, Inc. since September 2006. From November 2004 to September 2006, he served as Oncology Medical Director at Amgen Canada Inc. In 1991, he joined Glaxo Canada as a Research Scientist, later moving on to become Associate Director of Oncology Research at Adria Laboratories of Canada. In November 1994. Dr. Iglesias joined Eli Lilly Canada as Associate Director of Clinical Research. In June 2002, he was transferred to Sydney, in the role of Oncology Medical Advisor for Eli Lilly's Australian and Asian Operations, covering the Asia-Pacific region. He served several key global medical positions with Amgen Canada Inc. as well as Eli Lilly and Company in both Canada and Australia. He was employed at Celgene Corporation. His career includes senior positions at Apobiologix and Boston Biomedical. Dr. Iglesias advises Biothera Pharmaceuticals on clinical development, medical affairs and other functions related to the advancement of Imprime PGG. He has global clinical development experience in the pharmaceutical industry, having held senior positions with responsibility for cancer research and drug development. He has previously held multiple CMO and clinical development leadership roles at companies such as Abraxis, Celgene, Eli Lilly, Boston Biomedical, Apobiologix, Biothera Pharmaceuticals and Bionomics. In these roles, he has led the clinical development of biologics and small molecules in both solid and liquid tumors, bringing extensive experience to Senti’s growing oncology pipeline. While at Abraxis and Celgene. Dr. Iglesias designed and implemented the Phase 3 development of ABRAXANE® for the treatment of metastatic pancreatic, breast and non-small cell lung cancers. He is the author or co-author of more than 50 times and is an active member of ASCO, AACR and ESMO in the area of oncology. He has also served for many years as peer-reviewer for the Canadian Institutes of Health Research (Medical Research Council of Canada) within the University-Industry Programme. He has authored more than 70 peer-reviewed publications and is an active member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the European Society for Medical Oncology (ESMO). He earned his medical degree in Uruguay, completed a post-doctoral fellowship from the University of Toronto as well as fellowships at the Weizmann Institute of Science and Duke University. Dr. Iglesias began his career in oncology and hematology practice before transitioning to the biopharmaceutical industry. He graduated from Medical School in 1986. He holds M.D. in oncology and cancer biology from Montevideo School of Medicine (University of the Republic, Uruguay). Dr. Iglesias received additional medical research training at Duke University, University of Toronto in Canada and The Weizmann Institute of Science (Israel).

Positions